By sustaining an endogenous immune response, PD-1 or PD-L1 blocking antibodies have revolutionized cancer treatment and immune checkpoint blockade (ICB) has been established as a new standard of care for patients with various cancers. The gene discussed is PDCD1; the disease is cancer.